TSVT News and Press, 2seventy bio Inc. From 01/18/23

Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW Therapeutics Payment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried ...

Anticipate $470-$570M topline U.S. revenue Abecma (idecabtagene vicleucel) in 2023, shared equally with Bristol Myers Squibb (BMS) KarMMa-3 data to be presented at EBMT-EHA 5 th European CAR T-cell Meeting on February 10, 2023; 3L+ sBLA submission for Abecma targeted completio...

Collaboration Leverages 2seventy's Platform for T Cell Therapy Research and Development with Regeneron Antibodies and Bispecifics to Explore Multiplex Combination Approaches Regeneron Investing $20 million in 2seventy Equity; Regeneron to Fund 100% of Clinical Development Costs for Regene...

Summary Abecma U.S. sales in Q3 by BMS were $75 million. 2seventy bio is working on label expansion for Abecma. Platforms and pipeline imply strong growth during this decade. 2seventy bio ( TSVT ) is now a commercial-stage pharmaceutical company, as its cancer therapy ...

2seventy bio press release ( NASDAQ: TSVT ): Q3 GAAP EPS of -$1.76 beats by $0.09 . Revenue of $13.4M (-30.4% Y/Y) beats by $1.03M . For further details see: 2seventy bio GAAP EPS of -$1.76 beats by $0.09, revenue of $13.4M beats by $1.03M

Data from KarMMa-2 Cohorts 2a and 2c suggest potential for early treatment with Abecma in patients with second-line and newly diagnosed multiple myeloma Data suggest promising outcomes can be achieved treating patients with suboptimal response after transplant Resu...

Summary Chicago-based VectorBuilder, a gene therapy delivery CDMO, raised $57 million in a Series C round from China investors. JHM Biopharma completed a $28 million in a Series A1 round to support its biologic products for childhood genetic diseases, anti-aging, anti-virus and ne...

Initial focus on accelerating development of 2seventy bio’s MAGE-A4 program in solid tumors in China 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology co...

Summary Despite recent clinical and regulatory wins, bluebird bio's commercial success remains highly uncertain. Competition from next-generation gene therapies is closing in on lovo-cel (for Sickle Cell Disease), making a commercial success (if any) short-lived. Zynteglo's la...

Summary Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY. A successful interim readout for its KARMA-3 study sped up the clinical...